Investigating the role of ceramides in heart failure
Official title: Ceramides in Diastolic Heart Failure
Funded at University of Utah · NIH-11000007 · Data updated 2026-11-12
This study is looking at how certain fats in the body, called very long chain ceramides, might affect heart function in people with diastolic heart failure, and it aims to find new treatments that could help improve heart health for those patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project start | July 17, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $723,742 |
| NIH project number | 1R01HL170575-01A1 |
| Project ID | NIH-11000007 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with diastolic heart failure, particularly those with preserved ejection fraction.
✕Less likely to help
Patients with systolic heart failure or those without any form of heart failure may not benefit from this research.
What this research studies
This research focuses on understanding how very long chain ceramides contribute to the structural and functional changes in diastolic heart failure, particularly in patients with preserved ejection fraction. The study will explore the effects of genetic modifications and pharmacological interventions on ceramide levels and heart function in both animal models and human patients. By analyzing blood samples and heart biopsies, researchers aim to identify ceramides as potential therapeutic targets for improving heart health. Patients may have the opportunity to participate in trials assessing new treatments that could help manage their heart failure symptoms.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve heart function and quality of life for patients with diastolic heart failure.
How similar studies have gone: Previous research has shown promising results in targeting ceramides for therapeutic interventions in heart failure, indicating potential for success in this approach.
Where this research is happening
-
University of Utah
Salt Lake City, United States Active
Researchers
- Principal investigator: Holland, William L — University of Utah
- Study coordinator: Holland, William L
Related research
Other NIH-funded projects on the same topics.
-
AI-supported heart failure diagnosis and management in Rwanda
Aiming to help people with suspected heart failure in Rwanda get faster, more accurate diagnoses and better care using AI-guided ultrasound and care protocols.
-
AI-assisted heart failure diagnosis in Rwanda using focused ultrasound
An NIH-funded project will test whether AI-enhanced, easy-to-use heart ultrasound can help non-experts diagnose and manage heart failure in Rwanda.
-
HF endotypes in heart failure using ethical multi-modal AI and molecular data
A patient-friendly project that uses advanced AI and multiple kinds of health data to identify distinct heart failure subtypes that could guide personalized care.
-
Triple gene therapy approach to heal the heart after a heart attack
A new therapy combines three genetic approaches delivered by a virus to help the heart heal after a heart attack.
-
Digital-first heart failure care delivery in Uganda
A targeted program in Uganda tests a digital care plan to help people with heart failure manage their symptoms at home.
-
Digital-first heart failure care delivery in Uganda
A study to test digital self-care tools to help people with heart failure in Uganda manage symptoms and stay healthier.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.